Effects of fixed low-dose warfarin on hemostatic factors in continuous ambulatory peritoneal dialysis patients.
Increased coagulation factors found in dialysis patients may explain in part the high prevalence of thrombotic cardiovascular disease. Several studies showed low-dose warfarin is effective in decreasing coagulation factors and preventing thrombosis without increasing the risk of bleeding. To evaluate the effects of fixed low-dose warfarin therapy on thrombogenesis in continuous ambulatory peritoneal dialysis (CAPD) patients, 76 CAPD patients were assigned randomly to treatment and disease control groups. The treatment group received 2 mg of warfarin daily for 12 months. International normalized ratio (INR) of the prothrombin time and plasma levels of factor VII, D-dimer, von Willebrand factor (vWF), and plasminogen activator inhibitor-1 (PAI-1) were measured before and 3, 6, and 12 months after the start of medication. The same parameters were measured in 30 healthy volunteers at the beginning of the study and in the disease control group during the study period. Of 76 patients, 60 completed the study. Deaths from atherosclerotic cardiovascular disease (cerebral infarction or acute myocardial infarction) occurred in 1 patient in the treatment group (n = 29) and 3 in the disease control group (n = 31), which was not statistically significant. No major bleeding occurred during the study period. With administration of warfarin, there was a small increase in INR in the treatment group. CAPD patients at baseline had significantly higher plasma factor VII, D-dimer, vWF, and PAI-1 levels than normal controls. Warfarin therapy lowered plasma factor VII and D-dimer levels. No change was seen in vWF and PAI-1 levels. In the disease control group, these hemostatic factors showed no change during the study period. There was a negative correlation between serum albumin and INR in the treatment group during the study period. Fixed low-dose warfarin was effective in partially reversing the thrombogenic coagulation profile in CAPD patients without a big increase in the risk of bleeding.
Kim
S B
SB
Departments of Internal Medicine and Clinical Pathology, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, Korea.
Lee
S K
SK
Park
J S
JS
Chi
H S
HS
Hong
C D
CD
Yang
W S
WS
D000925:Anticoagulants / Q000008:administration & dosage* / Q000494:pharmacology; D001779:Blood Coagulation Factors / Q000187:drug effects*; D005167:Factor VII / Q000187:drug effects; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000187:drug effects; D006801:Humans; D019934:International Normalized Ratio; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory; D017395:Plasminogen Activator Inhibitor 1; D012709:Serum Albumin / Q000187:drug effects; D014859:Warfarin / Q000008:administration & dosage* / Q000494:pharmacology; D014841:von Willebrand Factor / Q000187:drug effects
D000925:Anticoagulants; D001779:Blood Coagulation Factors; D005338:Fibrin Fibrinogen Degradation Products; D017395:Plasminogen Activator Inhibitor 1; D012709:Serum Albumin; C036309:fibrin fragment D; D014841:von Willebrand Factor; D014859:Warfarin; D005167:Factor VII